[Cooperative Study of Surgical Adjuvant Chemotherapy for Colorectal Cancer (third report): five-year results after surgery]. 1993

O Nishida, and J Uchino, and K Kikuchi, and K Inokuchi, and N Komi, and T Hattori, and T Taguchi, and T Kondo, and O Abe, and N Ogawa
1st Dept. of Surgery, Hokkaido University School of Medicine.

Beginning in January 1984, in collaboration with 357 institutions nationwide, comparative studies on curative resection cases of colorectal cancer and a control group were conducted for 2 years. The following method of administration was employed; Group A received 12 mg/m2 of MMC on the day of operation, followed by 6 mg/m2 every 2 months 6 times. From the 2nd week after the operation, 800 mg/body/day of Futraful was administered for one year. Group B received no treatment. Altogether 2786 cases were collected and, excluding ineligible cases, 2477 evaluable cases were analyzed. There was no difference in either survival rate or disease free rate, but after the bias of background factors was corrected by the hazard model, the disease free rate was better with Group A, and there was a significant difference with the rectum. According to the Dukes classification, in the Dukes C cases with the rectum Group A had higher rate of survival, disease free rate and lower rate of metastasis to the liver and local recurrence of cancer.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D012004 Rectal Neoplasms Tumors or cancer of the RECTUM. Cancer of Rectum,Rectal Cancer,Rectal Tumors,Cancer of the Rectum,Neoplasms, Rectal,Rectum Cancer,Rectum Neoplasms,Cancer, Rectal,Cancer, Rectum,Neoplasm, Rectal,Neoplasm, Rectum,Rectal Cancers,Rectal Neoplasm,Rectal Tumor,Rectum Cancers,Rectum Neoplasm,Tumor, Rectal
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival
D016016 Proportional Hazards Models Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time. Cox Model,Cox Proportional Hazards Model,Hazard Model,Hazards Model,Hazards Models,Models, Proportional Hazards,Proportional Hazard Model,Proportional Hazards Model,Cox Models,Cox Proportional Hazards Models,Hazard Models,Proportional Hazard Models,Hazard Model, Proportional,Hazard Models, Proportional,Hazards Model, Proportional,Hazards Models, Proportional,Model, Cox,Model, Hazard,Model, Hazards,Model, Proportional Hazard,Model, Proportional Hazards,Models, Cox,Models, Hazard,Models, Hazards,Models, Proportional Hazard

Related Publications

O Nishida, and J Uchino, and K Kikuchi, and K Inokuchi, and N Komi, and T Hattori, and T Taguchi, and T Kondo, and O Abe, and N Ogawa
January 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
O Nishida, and J Uchino, and K Kikuchi, and K Inokuchi, and N Komi, and T Hattori, and T Taguchi, and T Kondo, and O Abe, and N Ogawa
March 1991, Gan to kagaku ryoho. Cancer & chemotherapy,
O Nishida, and J Uchino, and K Kikuchi, and K Inokuchi, and N Komi, and T Hattori, and T Taguchi, and T Kondo, and O Abe, and N Ogawa
September 1995, Gan to kagaku ryoho. Cancer & chemotherapy,
O Nishida, and J Uchino, and K Kikuchi, and K Inokuchi, and N Komi, and T Hattori, and T Taguchi, and T Kondo, and O Abe, and N Ogawa
August 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
O Nishida, and J Uchino, and K Kikuchi, and K Inokuchi, and N Komi, and T Hattori, and T Taguchi, and T Kondo, and O Abe, and N Ogawa
April 1988, Gan no rinsho. Japan journal of cancer clinics,
O Nishida, and J Uchino, and K Kikuchi, and K Inokuchi, and N Komi, and T Hattori, and T Taguchi, and T Kondo, and O Abe, and N Ogawa
October 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
O Nishida, and J Uchino, and K Kikuchi, and K Inokuchi, and N Komi, and T Hattori, and T Taguchi, and T Kondo, and O Abe, and N Ogawa
October 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
O Nishida, and J Uchino, and K Kikuchi, and K Inokuchi, and N Komi, and T Hattori, and T Taguchi, and T Kondo, and O Abe, and N Ogawa
February 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
O Nishida, and J Uchino, and K Kikuchi, and K Inokuchi, and N Komi, and T Hattori, and T Taguchi, and T Kondo, and O Abe, and N Ogawa
October 1996, Journal of surgical oncology,
O Nishida, and J Uchino, and K Kikuchi, and K Inokuchi, and N Komi, and T Hattori, and T Taguchi, and T Kondo, and O Abe, and N Ogawa
February 1968, American journal of surgery,
Copied contents to your clipboard!